Graham Capital Management, L.P. Cullinan Oncology, Inc. Transaction History
Graham Capital Management, L.P.
- $5.17 Billion
- Q2 2025
A detailed history of Graham Capital Management, L.P. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 19,277 shares of CGEM stock, worth $145,734. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,277
Previous 29,505
34.67%
Holding current value
$145,734
Previous $223,000
34.98%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
154Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$57.8 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$43.5 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$33.3 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$29.1 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$26.8 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $345M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...